The PARD6A antibody is a research tool targeting the PARD6A protein (Partitioning Defective 6 Homolog Alpha), a key component of cell polarity regulation. PARD6A, part of the PAR6 family, interacts with proteins like aPKC (atypical protein kinase C) and CDC42 to form the PAR3-PAR6-aPKC complex, essential for establishing and maintaining apical-basal polarity in epithelial cells. This polarity is critical for tissue organization, cell differentiation, and directional signaling. Dysregulation of PARD6A is implicated in cancer progression, particularly in epithelial-mesenchymal transition (EMT) and metastasis, as well as neurological disorders. The antibody is widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to study PARD6A's expression, localization, and interactions in cellular models or pathological tissues. Researchers leverage it to explore mechanisms underlying polarity loss in tumors, synaptic plasticity, and developmental biology. Its specificity and reliability make it valuable for identifying PARD6A in diverse samples, aiding discoveries in cell biology and disease pathways. Commercial variants vary in clonality, conjugates, and host species, requiring validation for experimental contexts.